Be Aware of Finerenone's Role for Diabetic Kidney Disease
November 2021
Finerenone (Kerendia) will be a new Rx for patients with chronic kidney disease (CKD) due to type 2 diabetes.
It's the first "nonsteroidal mineralocorticoid receptor antagonist"...and is approved to slow CKD progression and improve CV outcomes in these patients.
Finerenone is thought to limit fibrosis and inflammation in the kidneys and heart...by blocking effects of aldosterone.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote